Expression and biochemical analysis of the entire HIV-2 gp41 ectodomain: determinants of stability map to N- and C-terminal sequences outside the 6-helix bundle core  by Lay, Chan-Sien et al.
FEBS 28423 FEBS Letters 567 (2004) 183–188Expression and biochemical analysis of the entire HIV-2
gp41 ectodomain: determinants of stability map to N- and
C-terminal sequences outside the 6-helix bundle coreChan-Sien Laya,b, Kirilee A. Wilsonc, Bostjan Kobed, Bruce E. Kempa,e, Heidi E. Drummera,
Pantelis Poumbouriosa,*
aSt. Vincent’s Institute of Medical Research, 9 Princes Street Fitzroy, Vic. 3065, Australia
bDepartment of Microbiology and Immunology, University of Melbourne, Vic. 3058, Australia
cDepartment of Biochemistry and Cell Biology, Rice University, Houston, TX 77251-1892, USA
dDepartment of Biochemistry and Molecular Biology and Institute for Molecular Bioscience, The University of Queensland, Brisbane,
Qld 4072, Australia
eCSIRO Health Sciences and Nutrition, Vic., Australia
Received 19 March 2004; revised 16 April 2004; accepted 23 April 2004
Available online 3 May 2004
Edited by Michael R. BubbAbstract The folding of HIV gp41 into a 6-helix bundle drives
virus-cell membrane fusion. To examine the structural relation-
ship between the 6-helix bundle core domain and other regions of
gp41, we expressed in Escherichia coli, the entire ectodomain of
HIV-2ST gp41 as a soluble, trimeric maltose-binding protein
(MBP)/gp41 chimera. Limiting proteolysis indicated that the
Cys-591–Cys-597 disulﬁde-bonded region is outside a core
domain comprising two peptides, Thr-529–Trp-589 and Val-
604–Ser-666. A biochemical examination of MBP/gp41 chimeras
encompassing these core peptides indicated that the N-terminal
polar segment, 521–528, and C-terminal membrane-proximal
segment, 658–666, cooperate in stabilizing the ectodomain. A
functional interaction between sequences outside the gp41 core
may contribute energy to membrane fusion.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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The HIV envelope glycoprotein complex, gp120–gp41, me-
diates virus-cell membrane fusion, which leads to viral entry.
Binding by gp120 to CD4 and a chemokine receptor, CCR5
and/or CXCR4, triggers the refolding of gp41 into a trimer of
hairpins, which drives membrane fusion (for review see [1–3]).
gp41 is a class I fusion glycoprotein comprising an N-terminal
fusion peptide that initiates membrane fusion following in-
sertion into the target cell membrane. The fusion peptide is
linked through a polar segment to an extended N-terminal a-
helix that mediates glycoprotein trimerization. A disulﬁde-
bonded region and a C-terminal a-helical segment complete an* Corresponding author. Fax: +61-3-9416-2676.
E-mail address: apoum@ariel.its.unimelb.edu.au (P. Poumbourios).
Abbreviations: MBP, maltose-binding protein; TMD, transmembrane
domain; HTLV-1, human T cell leukemia virus type 1
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doi:10.1016/j.febslet.2004.04.054ectodomain which is anchored in the viral envelope by an 20-
residue transmembrane domain (TMD). The TMD precedes
an 150-amino acid cytoplasmic tail (for review see [3,4]).
The 6-helix bundle core domain of gp41 is composed of a
central trimeric coiled coil formed by three N-terminal a-helices
and three antiparallel C-terminal a-helices that pack into
grooves formed on the exterior of the coiled coil [5–9]. The
antiparallel packing of the C-terminal helices onto the coiled
coil is considered to translocate the TMD towards the site of
fusion peptide insertion, thereby juxtaposing viral and cellular
membranes for merger. These interhelical interactions bury up
to 3650 A2 of surface area [9], conferring stability to the 6-helix
bundle and providing energy to help drive membrane fusion.
The trimer-of-hairpins conformation has been observed for
other retroviruses [10–12], paramyxoviruses [13,14] and a ﬁlo-
virus (Ebola virus) [15,16], suggesting a common fusion
mechanism.
The poor solubility of gp41 when expressed in Escherichia
coli has necessitated the use of deletion mutagenesis together
with subsequent refolding and/or limited proteolysis to gen-
erate crystallizable protein [17–20]. These approaches have led
to the removal of functional determinants that are located
outside the 6-helix bundle core domain [5–9] such as the fusion
peptide and adjacent polar segment, the conserved disulﬁde-
bonded sequence linking the coiled coil and C-terminal helix,
and the C-terminal membrane-proximal segment. More com-
plete gp41 structures would enable a better understanding of
gp41 function and would provide new targets for the devel-
opment of fusion inhibitors.
We have expressed in E. coli the entire ectodomain of HIV-
2ST gp41 as a soluble, trimeric maltose-binding protein (MBP)/
gp41(506–666) chimera. Limited chymotrypsin proteolysis and
mass spectrometry indicated that the disulﬁde-bonded sequence
is outside a core domain that comprises two peptides, Thr-529–
Trp-589 and Val-604–Ser-666. By comparing the thermosta-
bilities of N- and C-terminally truncated chimeras, we found
that the N-terminal polar segment and C-terminal membrane-
proximal segment confer stability to the gp41 ectodomain. This
interaction, between sequences outside the gp41 core domain,
may provide additional energy to help drive fusion.ation of European Biochemical Societies.
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2.1. MBP/gp41 expression vectors
Amodiﬁed MBP/human T cell leukemia virus type 1 (HTLV-1) gp21
vector, pMBPL-gp21(338–425) [21], was used for expression of MBP/
gp41 chimeras. MBP was linked to gp41 through an Asn–Ala–Ala–Ala
linker incorporating a unique NotI site. PCR was used to generate the
HIV-2ST gp41 ectodomain fragments: Gly-506–Gln-672, Gly-506–Ser-
666, Ala-521–Ser-666, Ala-522–Ser-654, and Thr-529–Val-657, using
pJSP4/27-H6 [22] as the template. The forward primers, 50-CCCGC-
GAGGGCGGCCGCGGGTGTATTCGTGCTA, 50-ATAAGAAT-
GCGGCCGCGATGGGCGCGGCGTCCTTGACG, 50-C ACGAC-
AGCGGCCGCTGCAATGGGCGCGGCG and 50-CTGGGCGAC-
GCGGCCGCGACGCTGTCGGCTCAG, incorporate the NotI site
(underlined) and the N-terminal gp41 residues, Gly-506, Ala-521,
Ala-522, and Thr-529, respectively (bold). The reverse primers,
50-GCCAAAGTCGACTTAGCTATTTAATTTTTGTAG, 50-ATG-
GCCGACGTCGACTTAAACATCCCAGCTATTTAATTTTTG,
50-CTGAATATAGTCGACTTAGGAGGTTAAATCAAACCA and
50-CCGGCCCTAGTCGACTTACTGAATATATTTGATCCAG, in-
corporate the C-terminal gp41 amino acids Ser-654, Val-657, Ser-666
and Gln-672, respectively (bold), a stop codon (italics) and a SalI site
(underlined). The PCR products were ligated into the MBP expression
vector through NotI–SalI. DNA sequences were conﬁrmed using ABI
prism BigDye terminator (Applied Biosystems, Foster City, CA).
2.2. Expression and puriﬁcation of MBP/gp41 chimeras
MBP/gp41 chimeras were induced at room temperature using 0.2
mM isopropyl-b-D-thiogalactopyranoside in E. coli strain BL21(DE3).
After 18 h, the pelleted cells were lysed by sonication in ice-cold MES
buﬀer (100 mM 2-[N-Morpholino]ethanesulfonic acid, pH 5, and 300
mM NaCl, and 1 mM EDTA) and clariﬁed by centrifugation (1 h at
20 000 g). MBP/gp41 was aﬃnity-puriﬁed using amylose–agarose as
recommended (New England Biolabs). MBP/gp41 oligomers were
further puriﬁed by gel-ﬁltration chromatography using Superdex 200
(HiLoad 26/60) equilibrated in MES buﬀer. Gel-ﬁltration experiments
were calibrated with blue dextran, ferritin (440 kDa), aldolase (158
kDa) and ovalbumin (43 kDa) (Amersham Biosciences).
2.3. Analytical ultracentrifugation
MBP/gp41(522–654) oligomers were subjected to sedimentation
equilibrium on a Beckman XL-A analytical ultracentrifuge equipped
with Absorbance Optics, an An-60Ti rotor and ﬁlled-epon centerpieces
(12 mm path length). MBP/gp41(522–654) oligomers at 0.8, 0.4 and
0.08 mg/ml in MES buﬀer, pH 6.5, were centrifuged at 20 C for 16 h,
at 12 000 rpm. The ﬁnal equilibrium distributions were determined
from absorption measurements at 205, 280 and 295 nm. Theoretical
partial speciﬁc volume calculated from the amino acid composition of
HIV-2ST MBP/gp41(522–654) was 0.743 and the solvent density of the
MES buﬀer was calculated to be 1.013 gml1 at 20 C. To calculate
molecular weight, data were ﬁtted using the SEDEQ1B programFig. 1. Alignment of gp41 ectodomain sequences from HIV-2ST, SIVmac239 a
numbering is used). The N- and C-terminal a-helices of the SIVmac239 [9] and H
residues encompassed by the protease-resistant core of SIVmac239 [17] and H
residues forming the intramolecular disulﬁde are shown in bold type. The ch
for MBP/gp41(506–666) are indicated by arrows and labeled CHY.(provided by Allen Minton, NIH, Bethesda, MD) to a single species
model. No systematic deviation of the residuals was evident in any
concentration set. The optical density at 280 or 295 nm as a function of
radial distance was ﬁtted by global analysis assuming a single solute.
2.4. In vitro oxidation
MBP/gp41 trimers (0.09 mg/ml) were oxidized using 1.5 mM copper
II, 4.5 mM phenanthroline in 100 mM Tris, pH 8.5, for 18 h at room
temperature. The oxidized protein was repuriﬁed using a Superdex 200
(HiLoad 26/60) gel-ﬁltration column equilibrated in MES buﬀer or 50
mM glycine, pH 6.5, and 300 mM NaCl. The presence or absence of
free sulfhydryls in MBP/gp41 was determined by treating with the
alkylating agent, 1,4-vinylpyridine (Sigma) followed by electrospray
mass spectrometry as described [21,23].
2.5. Limited chymotrypsin proteolysis of MBP/gp41 chimeras
MBP/gp41(506–666) trimer (0.5 mg/ml) was proteolyzed with se-
quencing-grade chymotrypsin (Roche) at a 1:50 ratio of protease to
protein (w/w) in 100 mM Tris, pH 8.5. Proteolysis was quenched by the
addition of 0.1% triﬂuoroacetic acid prior to mass spectrometry.
2.6. Electrospray mass spectrometry
Methanol/chloroform-precipitated proteins were resuspended in
15% (v/v) acetic acid, 30% (v/v) acetonitrile and directly infused into
the mass spectrometer using a nanoelectrospray ion source (PE Sciex
API III instrument) and NanoES spray capillaries (Protana Engi-
neering A/S). Ion spectra were visualized with Tune 2.5-FPU software
and deconvoluted by hypermass reconstruction using MacSpec 3.3 (PE
Sciex).
2.7. Thermal aggregation assays
The thermostability of MBP/gp41 trimers was assessed using a
thermal aggregation assay [23]. Brieﬂy, puriﬁed MBP/gp41 trimers
were exchanged into 50 mM glycine, pH 6.5, 300 mM NaCl, using a
Superdex 200 HR (10/30) column. The trimers were heat-treated at 48,
49 or 50 C for 5 min, cooled on ice, and then centrifuged at 16 000 g
for 4 min prior to gel ﬁltration on a Superdex 200 HR (10/30) column
at a ﬂow rate of 0.5 mlmin1.3. Results
3.1. Use of MBP as a solubilization partner for the entire
ectodomain of HIV-2ST gp41
We investigated whether the MBP expression system could
be used for the bacterial expression of the HIV gp41 ectodo-
main in soluble form. We prepared a chimera composed of
MBP linked through a trialanine linker to an HIV-2ST gp41nd HIV-1HXB2R and the organization of functional elements (HIV-2ST
IV-1HXB2R [8] 6-helix bundles are indicated as dark gray cylinders. The
IV-1HXB2R [18] gp41 are highlighted in light gray. The conserved Cys
ymotrypsin cleavage sites identiﬁed in this study by mass spectrometry
C.-S. Lay et al. / FEBS Letters 567 (2004) 183–188 185ectodomain fragment, Ala-522–Ser-654, MBP/gp41(522–654)
(Fig. 1). Puriﬁed MBP/gp41(522–654) eluted as a symmetrical
peak with Superdex 200 gel ﬁltration (Fig. 2A). The trimeric
state of this protein was conﬁrmed by sedimentation equilib-
rium ultracentrifugation, the experimental data closely ﬁtting0
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Fig. 2. (A) Superdex 200 (26/60) gel-ﬁltration proﬁle of MBP/
gp41(522–654) oligomer. The column was calibrated using ferritin (440
kDa), aldolase (158 kDa) and ovalbumin (43 kDa) (arrows). Vo, void
volume. Flow rate: 2 mlmin1. (B) Sedimentation equilibrium proﬁle
of MBP/gp41(522–654) oligomer. The log of the optical density at 295
nm as a function of the square of the radial distance is shown (closed
circles). The lines of best ﬁt for theoretical tetramer (dotted line) and
trimer (dashed line). No systematic deviation from the residuals was
evident. (C) Superdex 200 (26/60) gel-ﬁltration proﬁles of MBP/
gp41(506–666) and MBP/(506–672) chimeras following elution from
amylose agarose. Flow rate: 2 mlmin1. Dashed line indicates the
elution position of trimeric MBP/gp41(522–654).the slope of a theoretical trimer (168 kDa) with an observed
molecular mass of 174 5.2 kDa (Fig. 2B). MBP/gp41 chi-
meras incorporating homologous HIV-1 (YU2 and BH8
strains), HIV-2 (ROD) and SIV (MAC239) sequences gave
lower yields of protein of heterogeneous oligomeric structure
(data not shown). We, therefore, used the HIV-2ST sequence to
model the gp41 ectodomain.
We next determined if MBP could be used as a solubilization
partner for the entire HIV-2ST gp41 ectodomain, including the
fusion peptide. MBP/gp41(506–666) eluted as two peaks with
Superdex 200 gel ﬁltration: a high-molecular weight aggregate
and a minor species that co-eluted with MBP/gp41(522–654)
trimer (Fig. 2C). Extension of the C terminus by six residues in
MBP/gp41(506–672) resulted in aggregated protein. These
data are consistent with the HIV-2ST gp41 ectodomain termi-
nating at Ser-666 [24,25], with residues 667–672 likely to rep-
resent a portion of the TMD.
3.2. Oxidation of the gp41 disulﬁde bond in vitro
The gp41 ectodomain contains two conserved cysteines,
Cys-591 and Cys-597, forming an intramolecular disulﬁde
bond that is required for correct Env glycoprotein folding and
function [26]. We assessed the redox state of MBP/gp41(506–
666) by using mass spectrometry to monitor the alkylation of
free sulfhydryls by 1,4-vinylpyridine. The treatment of MBP/
gp41(506–666) with 1,4-vinylpyridine led to the addition of 214
Da, consistent with both cysteines being reduced (Figs. 3A and
B). Disulﬁde bond formation was induced using copper II[1,10
phenanthroline]3-catalyzed oxidation in vitro. The mass of
oxidized MBP/gp41(506–666) trimer was not altered by 1,4-
vinylpyridine treatment, consistent with quantitative disulﬁde
bond formation (Fig. 3C). The trimeric structure of MBP/
gp41(506–666) was retained following the oxidation procedure
as indicated by gel-ﬁltration chromatography (data not
shown). Approximately 5% of the puriﬁed oxidized trimer
migrated as high-molecular weight disulﬁde-linked oligomers
in SDS–PAGE under non-reducing conditions (Fig. 3D, as-
terisk) indicating that the yield of intrachain disulﬁde forma-
tion was approximately 95%. This procedure yielded
approximately 0.3 mg oxidized MBP/gp41(506–666) trimer per
litre of bacterial culture.
3.3. Limited chymotrypsin proteolysis of MBP/gp41(506–666)
The availability of MBP/gp41(506–666) now allows an as-
sessment of the gp41 core domain by limited proteolysis in the
context of an intact, trimeric ectodomain. Oxidized MBP/
gp41(506–666) trimers were treated with chymotrypsin (pro-
tease:protein ratio¼ 1:50 [w/w]) at 37 C for various times.
Mass spectrometry of a 30-s incubation revealed two major
proteolytic products, MBP/gp41(G506-W589) (49 685 Da) and
MBP/gp41(G506-W603) (51 276 Da) (Fig 4A); a peak corre-
sponding to Gly-590–Trp-603 was not observed. Thus,
chymotrypsin cleaves rapidly on either side of the Cys-591–Cys-
597 disulﬁde indicating that this sequence is exposed and likely
forms a poorly ordered structure outside the core domain.
After 60 min of incubation, the largest gp41 peptides detected
were fragments of 7039 Da, corresponding to gp41(T529-
W589) (Fig 4B), and 7679 Da, corresponding to gp41(V604-
S666) (Fig 4C). Although we observed MBP/gp41(506–508)
(40 814 Da) at the 60 min time point, a species correspond-
ing to gp41(V509-L528) was not detected, perhaps due to
poor ionization of this peptide (data not shown). These data
Fig. 3. (A) Electrospray mass spectrometry of MBP/gp41(506–666)
trimer; (B) alkylation of MBP/gp41(506–666) trimer with 1,4-vinyl-
pyridine adds 214 Da, consistent with the presence of two free sul-
fhydryls; (C) in vitro-oxidized MBP/gp41(506–666) is not modiﬁed by
treatment with 1,4-vinylpyridine, consistent with disulﬁde formation;
(D) SDS–PAGE under reducing (+ bME) and non-reducing () bME)
conditions of MBP/gp41(506–666) after (lanes 1) and before (lanes 2)
oxidation in vitro.
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Fig. 4. Electrospray mass spectrometry of MBP/gp41(506–666) di-
gested with chymotrypsin at 37 C for 30 s, Panel A and 60 min, Panels
B and C. Panel A, 49 685 and 51 276 Da species correspond to MBP/
gp41(506–589) and MBP/gp41(506–603), respectively; Panel B, 7039
Da species corresponds to gp41(529–589); Panel C, 7679 Da species
corresponds to gp41(604–666). The 7097 Da species observed in Panel
B does not correspond to a theoretical chymotryptic peptide of gp41
nor MBP. This species was also observed at the 30 s time point and
may be derived from a contaminant.
186 C.-S. Lay et al. / FEBS Letters 567 (2004) 183–188indicate that the core domain of gp41 comprises the N- and C-
terminal a-helical segments gp41(T529-W589) and gp41(V604-
S666), respectively. These peptide components of the putative
core domain obtained from soluble HIV-2ST gp41 ectodomain
are larger than previously determined by limited proteolysis of
insoluble HIV-1 and SIV gp41 constructs (Fig. 1) [17–19].
3.4. N- and C-terminal sequences external to the 6-helix bundle
domain confer stability to the gp41 ectodomain
We next constructed the MBP/gp41(529–666) chimera based
on the assumption that Thr-529–Ser-666 encompasses the gp41
core. Unexpectedly, this protein eluted as a high-molecular
weight aggregate with little evidence of trimer in gel-ﬁltrationexperiments (Fig. 5). Trimerization ability was restored by a 9-
residue C-terminal truncation [chimera MBP/gp41(529–657)]
or by extending the N-terminal residues from Thr-528 to Ala-
521 [chimera MBP/gp41(521–666)]. These data indicate that
residues 521–528, comprising the polar linker between the fu-
sion peptide and coiled coil [27], are required for the stable
accommodation of the membrane-proximal residues, 658–666,
within a trimeric chimera.
We next compared the stability of in-vitro-oxidized MBP/
gp41(529–657), MBP/gp41(521–666) and MBP/gp41(506–666)
trimers by using a thermal aggregation assay where the tem-
perature-dependent conversion of trimer to high-molecular
weight aggregate is monitored by gel-ﬁltration chromatogra-
phy [23]. The trimeric structure of MBP/gp41(529–657) was
retained after a 5-min heat treatment at 48 C, whereas 80%
of this protein formed aggregates after treatment at 50 C
(Fig. 6). The heat treatment may cause the aggregation of gp41
trimers through the exposure of hydrophobic regions. Alter-
natively, thermal aggregation may occur through association
of denatured gp41 domains (MBP retains its monomeric
structure even after treatment at 55 C for 5 min, data not
shown). By contrast, MBP/gp41(521–666) resisted aggregation
with >95% of this protein retaining its trimeric structure fol-
lowing the 50 C treatment. Inclusion of the fusion peptide in
MBP/gp41(506–666) led to increasing amounts of aggregate
forming after 48 and 49 C treatments, respectively (Fig. 6),
and the 50 C treatment resulting in total protein precipitation
(data not shown). Thus, the N-terminal polar linker 521–528
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Fig. 6. Thermal aggregation-gel-ﬁltration analysis of MBP/gp41 chi-
meras. The eﬀects of a 5 min treatment at the indicated temperatures
on the trimeric structures of in vitro oxidized MBP/gp41(529–657),
MBP/gp41(521–666) and MBP/gp41(506–666) were monitored by Su-
perdex 200 HR (10/30) gel ﬁltration at a ﬂow rate of 0.5 mlmin1. The
treatment of MBP/gp41(506–666) for 5 min at 50 C resulted in pre-
cipitation of the total protein.
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MBP/gp41(522–654). Flow rate: 2 mlmin1.
C.-S. Lay et al. / FEBS Letters 567 (2004) 183–188 187and C-terminal membrane-proximal sequence 658–666, which
are located outside the 6-helix bundle core domain, confer
stability to the gp41 ectodomain against exposure of hydro-
phobic sequences. However, the fusion peptide has a destabi-lizing inﬂuence on the ectodomain, consistent with the
observations that hydrated class I fusion peptides are unstable
[28].4. Discussion
We have shown that the entire ectodomain of HIV-2 gp41
(Gly-506–Ser-666) can be obtained as a soluble trimer when
MBP is used as an N-terminal fusion partner. MBP may have
general utility for the soluble expression of retroviral fusion
glycoproteins as we have also used this approach to express the
entire HTLV-1 gp21 ectodomain in soluble form [23]. This
capacity to obtain the entire gp41 ectodomain enabled for the
ﬁrst time, a biochemical assessment of the relationship between
the gp41 core domain and structural elements located outside
the core.
The antiparallel N- and C-terminal a-helical core segments
of retroviral TMs are linked through the disulﬁde-bonded se-
quence. We found that the gp41 disulﬁde does not form
spontaneously in E. coli, but its formation can be induced by
oxidation in vitro with copper II [1,10 phenanthroline]3. De-
spite the presence of the disulﬁde in MBP/gp41(506–666),
limited proteolysis indicated that this region is exposed and
possibly poorly ordered compared to the core domain. In
contrast, the corresponding region in other retroviruses, in-
cluding HTLV-1 and murine leukemia virus, forms a protease-
resistant structure mediating a chain reversal that is stabilized
by a polar interaction between the disulﬁde-bonded loop and
the base of the coiled coil [10,11,23,29]. Furthermore, the di-
sulﬁde-bonded region of gp41 is dispensable for 6-helix bundle
formation [6,8], whereas the polar interaction between the di-
sulﬁde-bonded region and the coiled coil is an essential com-
ponent of the HTLV-1 trimer of hairpins core domain [30].
These structural diﬀerences may be reﬂected in functional
diﬀerences observed for this region in HIV-1 and HTLV-1
TMs, the gp41 disulﬁde-bonded region appearing to form an
adaptable structure important for gp120 association whereas
its gp21 counterpart mediates fusion activation [30–32].
The protease-resistant core domain identiﬁed in this study,
Thr-529–Trp-589 and Val-604–Ser-666, includes an additional
4 N-terminal and 11 C-terminal residues, respectively, when
compared to previous investigations employing proteolysis of
insoluble protein lacking the fusion peptide, polar linker and
membrane-proximal regions (see Fig. 1) [17,18]. These addi-
tional N- and C-terminal sequences may be structured as they
are resistant to chymotrypsin despite the presence of several
protease targets (Leu-530, Trp-655, Phe-658, Trp-661 and Leu-
664). The additional sequences encompass structural and
functional elements that have been observed in other retrovi-
ruses. For example, the analogous N-terminal residues of
HTLV-1 gp21 form a functionally important N cap that ter-
minates the coiled-coil forming helices [11,30], while the C-
terminal residues encompass a tryptophan-rich motif shown to
be important for HIV-1 glycoprotein fusogenicity [33,34].
The MBP/gp41(529–666) chimera, based on the protease-
resistant core, was obtained as a high-molecular weight
aggregate from E. coli. However, an 8-residue N-terminal ex-
tension of the gp41 domain, or a 9-residue C-terminal trun-
cation restored trimerization. The N-terminal polar linking
segment, 521–528, is thus required for the accommodation
188 C.-S. Lay et al. / FEBS Letters 567 (2004) 183–188of the membrane-proximal segment, 658–666. The C-terminal
segment, 658–666, may promote aggregation of trimers, unless
shielded by the polar segment, 521–528. MBP/gp41(521–666)
containing these terminal sequences exhibited greater ther-
mostability than MBP/gp21(529–657), lacking these elements.
These terminal regions may interact functionally or directly to
stabilize the ectodomain. Munoz-Barroso et al. [34] showed
that a cluster of aromatic residues within the membrane-
proximal segment of HIV-1 gp41 is important to drive fusion
beyond the pore formation phase. An interaction between
hydrophobic residues within the N-terminal polar linking
segment and the membrane-proximal aromatic cluster may
provide energy for pore expansion and the completion of fu-
sion. We have observed conserved functional roles for these
regions in the HTLV-1 retrovirus. Sequential C-terminal
truncation of full-length MBP/gp21 ectodomain is associated
with incremental decreases in trimer of hairpins stability [23],
while an I334A substitution within the polar linking region
both decreases MBP/gp21 stability and blocks the pore ex-
pansion phase of fusion (Wilson et al., 2004; submitted).
Functionally important interactions between membrane-
proximal sequences extend to the Orthomyxoviridae family of
viruses, which also utilize a class I fusion mechanism. The tight
binding between a C-terminal extended sequence and the N-
terminal end of the coiled coil, including the N cap, of inﬂu-
enza virus HA2 promotes the initial lipid-mixing phase of
fusion [35].
The structures of the HIV-1HXB2R and SIVMAC239 6-helix
bundles superimpose with a root mean square deviation of less
than 1 A [9], while sharing 53.5% amino acid sequence identity.
The HIV-2ST gp41 core shares 51.3% and 86.8% amino acid
sequence identity, respectively, with HIV-1HXB2R and
SIVMAC239, indicating that their structures are likely to be very
similar. The N- and C-terminal sequences of HIV-2ST gp41,
found in this study to be important for ectodomain stability,
are even more closely related (57.6% identity) to their HIV-1
counterparts than are the 6-helix bundle cores. Our ﬁndings
for HIV-2 gp41 may, therefore, also apply to HIV-1 gp41. The
novel recombinant forms of HIV-2 gp41 identiﬁed in this study
may facilitate future structural investigations of these N- and
C-terminal functional regions to provide a more complete
understanding of viral fusion.
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